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a broader understanding of the inﬂ uence of epidemics on health care systems. It is 
possible to investigate feedback of health service structure changes and reimbursement 
decisions on prevalence and effects of infectious diseases.
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IS IT POSSIBLE TO OBTAIN WILLINGNESS-TO-PAY ESTIMATES IN 
EUROPE? A VALIDITY TEST OF STATED PREFERENCES FOR 
HEPATITIS-B TREATMENTS
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BACKGROUND: Because health care is highly insured in Europe, many discrete-
choice experiment (DCE) researchers have concerns about the feasibility of obtaining 
valid willingness-to-pay (WTP) estimates. OBJECTIVES: To test the validity of WTP 
estimates obtained from patient DCE data in 5 countries. METHODS: Adults with a 
self-reported physician diagnosis of hepatitis B in 4 European countries (France, 
Germany, Spain, and Italy) and Turkey completed a web-enabled, DCE. The survey 
presented patients with a series of 12 trade-off questions, each including a pair of 
hypothetical hepatitis-B treatments described by efﬁ cacy, two side-effect risks, weight 
of evidence, and cost. All the subjects saw cost levels of c0, c10, and c25. Half the 
subjects evaluated an additional cost level of c75 and half the subjects evaluated an 
additional cost level of c150 per month. RESULTS: 664 subjects completed the survey. 
About 15% of subjects refused to accept any tradeoffs between costs and outcome 
attributes, while the remainder perceived no signiﬁ cant difference between costs of c0 
and c10. The difference in importance weights between the highest cost levels in each 
treatment arm was signiﬁ cantly different (P < 0.000). The importance weight of one 
additional euro in cost of c25 or greater was negative, highly signiﬁ cant, and equal 
in both arms (p = <0.000). Compared to a treatment with 70% probability of achiev-
ing no detectable virus after 5 years and no side-effect risk, the increase in value to 
patients of a hypothetical treatment that has 95% effectiveness, 1% 5-year fracture 
risk, and 1% 5-year risk of kidney disease is an additional c34 (c17–c51) per month. 
CONCLUSIONS: We obtained DCE responses in a split-sample test of cost sensitivity 
that were consistent with theoretical requirements. Results suggest that it is possible 
to obtain valid WTP estimates in a properly motivated European DCE. 
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THE EFFICACY OF DONEPEZIL AND MEMANTINE FOR TREATING 
BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA 
(BPSD) IN PATIENTS WITH ALZHEIMER’S DISEASE: SYSTEMATIC 
REVIEW AND META-ANALYSIS
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OBJECTIVES: Behavioral and psychological symptoms of dementia (BPSD) in 
Alzheimer’s disease (AD) greatly increase caregiver burden and often trigger nursing 
home placement. a systematic review of double-blind randomized controlled trials 
(RCTs) was conducted to compare the ability of donepezil and memantine to manage 
BPSD in AD. METHODS: MEDLINE, EMBASE, Cochrane Library, and hand 
searches identiﬁ ed 4739 citations, of which 16 studies had Neuropsychiatric Inventory 
(NPI) data suitable for meta-analysis (6 memantine and ten donepezil trials). All trials 
were placebo-controlled, and no head-to-head comparisons of the two drugs were 
identiﬁ ed. a random-effects meta-analysis was conducted using AD severity subgroups 
to investigate heterogeneity between trials. Thereafter meta-regression was conducted 
using study level covariates as potential predictors of between-treatment weighted 
mean difference (WMD) in NPI score. RESULTS: Unadjusted random effects meta-
analysis of all 16 RCTs found signiﬁ cant between-study heterogeneity (all studies I2 = 
64.4%; donepezil vs. placebo WMD −1.84, 95%CI −3.57, −0.10, I2 = 61%; meman-
tine monotherapy vs. placebo WMD −1.19, 95% CI −3.70, 1.32, I2 = 68.7%; meman-
tine + AChEI combination therapy vs. placebo WMD −1.68 95% CI −5.70, 2.33, I2 
= 80.4%). Meta-regression that stratiﬁ ed studies into four AD severity groups mea-
sured by Mini-Mental State Exam (MMSE) (severe 0–9, moderately-severe 10–14, 
moderate 15–20 and mild 21–26) and controlling for age at baseline, found these 
covariates accounted for most (59.85%) of the between-study variance. Using this 
meta-regression model, the pooled NPI score for donepezil showed signiﬁ cant 
improvement compared to placebo (MD −1.50; 95% CI −2.63, −0.36) whereas this 
was not the case for memantine vs. placebo (MD −1.25; 95% CI −2.63, 0.13). CON-
CLUSIONS: Donepezil was associated with signiﬁ cant improvement in the manage-
ment of BPSD in AD patients compared to placebo, whereas memantine failed to show 
a signiﬁ cant improvement versus placebo in the management of these symptoms.
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OBJECTIVES: To assess the all-cause medication discontinuation rate in matched 
cohorts of patients with schizophrenia at risk of nonadherence who were initiated on 
depot or oral antipsychotics and followed over 12 months. METHODS: At study 
entry, outpatients with schizophrenia from Australia, Mexico, Romania, and Taiwan 
were switched, due to clinician-perceived medication non-adherence risk, from their 
current oral antipsychotic to either a depot or different oral antipsychotic in this 
12-month, prospective observational study. Patients were compared on all-cause medi-
cation discontinuation rates, deﬁ ned as a switch from the initiated medication or its 
augmentation with another antipsychotic. Patients initiated on depot were matched 
with those initiated on any oral antipsychotic, using full optimal and nearest neighbour 
(greedy) matching algorithms. The Rank-based Mahalanobis metric was chosen as the 
distance based on propensity score plus other relevant covariates, with country and 
antipsychotic class used for exact matching. RESULTS: Based on the full optimal 1:1 
matching, only 40 of the 43 original depot initiators were matched to a corresponding 
oral initiator. After matching, there were no statistically signiﬁ cant differences between 
the depot and oral cohorts on any of the study entry covariates examined. During the 
12-month study, 20% of depot patients discontinued their initial medication, com-
pared with 40% of oral patients (survival curve comparison, p = 0.025; Hazard Ratio 
= 0.33 [0.12, 0.92], p = 0.033, NNT = 6 [3,-34]). No statistically signiﬁ cant differences 
were found between the two groups on other assessed outcomes, including hospitaliza-
tion, length of stay, and quality of life and disease severity measures. CONCLUSIONS: 
Systematic matching of patients initiated on depot with those initiated on oral anti-
psychotics showed that the oral-initiated patients were statistically signiﬁ cantly more 
likely to discontinue their medication. Findings highlight the importance of systematic 
matching of patient cohorts when comparing treatment outcomes in observational 
studies.
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OBJECTIVES: Hospital admission is a common and costly event in schizophrenia. An 
analysis of phase 1/1A CATIE clinical trial data assessed various patient socio-demo-
graphic and clinical characteristics in relation to risk of psychiatric hospital admission. 
METHODS: We followed 1460 study participants from baseline until ﬁ rst schizophre-
nia-related hospital admission, study medication discontinuation, or 18 months. Step-
wise Cox regression models assessed the adjusted hazard ratio (AHR) of hospital 
admission by baseline patient socio-demographic and clinical characteristics. 
RESULTS: In 869 person-years of follow-up, 203 patients were hospitalized. The adjusted 
hazards of hospital admission were not signiﬁ cantly related to patient socio-demographic 
characteristics. Increased risk of admission was linked to early age (<17 years) of ﬁ rst 
antipsychotic treatment (AHR: 2.09; 95%CI: 1.45–3.02), psychiatric hospital admission 
in past year (AHR: 2.92; 95%CI: 2.18–3.90), and DSM-IV alcohol (AHR: 1.55; 95%CI: 
1.15–2.08) and drug (AHR: 1.50; 95%CI: 1.13–2.00) use disorders in the past 5 years. 
Severe (5–7) as compared with mild (1–3) baseline global clinical severity (AHR: 1.51; 
95%CI: 1.03–2.23) (CGI-I), high (>20) as compared with low (7–15) positive symptoms 
(AHR: 1.53; 95%CI: 1.08–2.16) (PANSS-positive subscale), and low (0–2.2) as compared 
with high (>3.1) social function (AHR: 1.47; 95%CI: 1.04–2.08) (Heinrichs-Carpenter 
QLI) were related to signiﬁ cantly increased risk of hospital admission. As compared with 
olanzapine treatment assignment, quetiapine (AHR: 2.12; 95%CI: 1.37–3.27), perphen-
azine (AHR: 1.64; 95%CI: 1.02–2.65), and ziprasidone (AHR: 2.67; 95%CI: 1.62–4.39), 
though not risperidone (AHR: 1.40; 95%CI: 0.89–2.21), were also associated with 
increased hospital admission risk. Self-rated physical health (SF-12 PCS) and drug attitudes 
(DAI) were not signiﬁ cantly related to risk. CONCLUSIONS: In the treatment of schizo-
phrenia, efforts to lower hospital admission risk should focus on patients with early 
onset disorders, recent inpatient admissions, severe positive symptoms, high global 
clinical severity, poor social function, and comorbid substance use disorders and should 
select an appropriate antipsychotic medication.
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A PHASE IV STUDY OF THE EFFECTIVENESS OF QUETIAPINE 
EXTENDED RELEASE 600 MG ONCE A DAY TO CONTROL THE 
SYMPTOMS OF MANIC PHASE OF BIPOLAR DISORDER: THE EMMY 
TRIAL
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OBJECTIVES: To assess the efﬁ cacy of a 600 mg/day dose of Quetiapine Extended 
Release administrated once a day at evening as monotherapy or in combination with 
lithium or valproate for 21 days. METHODS: A multi-center phase IV study was 
designed to assess the efﬁ cacy of quetiapine extended release 600 mg per day either 
as monotherapy or combined therapy with lithium and valproic acid in the treatment 
